Christine Goertz, DC, PhD
April 9th, 2013
The TACT Investigators Respond to Questions
Gervasio Antonio Lamas, MD, Daniel Mark, Christine Goertz, DC, PhD, Robin Boineau, M.D., M.A., Kerry L. Lee, Ph.D. and Harlan M. Krumholz, MD, SM
The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?